Who is behind JTTT? JATT (biotech serial)
The people who set JATT III Acquisition Corp up, what they have done before, and what happened to the shareholders who backed their earlier vehicles — every outcome cited to an SEC filing.
Deal completion: 1/1 resolved vehicles closed a deal (100%); 0 liquidated, 0 terminated. Gated ×0.93 by measured post-close quality (43/100): closing deals that ended below trust value is not a completed job, so only 93% of the completion credit is earned. Full credit resumes at outcome quality 50/100 (the median deSPAC ending at trust value); the gate can never exceed 1×. Small sample — the shrink below keeps this near neutral.
Mixed record · low confidence — the same inputs always produce the same score.
Track record
The fleet this sponsor runs today, and the SEC-verified fate of every prior vehicle we have traced.
- JATT Acquisition Corp · 2021→ Zura BioZURACompleted
JATT — biotech serial led by Dr. Someit Sidhu. Prior-vehicle track record (SEC-verified via formerNames): JATT Acquisition Corp COMPLETED → Zura Bio (ZURA, Nasdaq, still listed). Current vehicle JATT (in-deal) plus one searching. Net: 1 completed deSPAC (listed). Sources: SEC EDGAR submissions API (formerNames) + full-text search, efts.sec.gov. — research profile — JATT is a biotech-focused serial SPAC sponsor led by Dr. Someit Sidhu, a serial biotech entrepreneur and former McKinsey consultant who trained at Oxford Medical School. Sidhu has founded or co-founded multiple biotech ventures including Khanda Therapeutics, Izana Bioscience (sold to Roivant in 2020), Pathios Therapeutics, and Akaza Bioscience. The JATT platform has now produced at least three vehicles: JATT Acquisition Corp (JATT I), JATT II Acquisition Corp (JATT II), and a filed JATT III. The sponsor entity for JATT II is JATT Ventures II L.P. The management team is rounded out by CFO Nicholas Fernandez, a seasoned finance executive with prior stints as COO/CFO of Athanor Capital and CFO of Jefferies' Asset Management and Alternative Investments divisions, along with a board featuring Verender S. Badial (former MD in Equity Capital Markets at Societe Generale and ABN AMRO Rothschild, with 48 public market deals to his credit), Arjun Goyal (founder of Vianti Capital, co-founder of Vida Ventures with $4B in M&A), Dr. Jonathon Kluft (former VP at Roivant Sciences, instrumental in forming Immunovant, Urovant, and Pulmovant), and Christopher Staral (founder/CIO of Triple Helix Investments, former biotech equity research at Goldman Sachs). Guggenheim Securities has served as sole bookrunner across the JATT II offering. JATT I completed its business combination with Zura Bio Limited in March 2023, a deal with a $215 million pro forma enterprise value. The transaction was originally structured to deliver up to $189 million in gross proceeds ($139 million from trust assuming no redemptions, plus $50 million in PIPE and forward purchase commitments), but Zura Bio ultimately netted only approximately $65 million in gross cash proceeds, implying substantial redemptions by public shareholders. The post-de-SPAC performance was poor: Zura Bio (ZURA) traded down approximately 43% from the $10 offer price, according to Renaissance Capital. Sidhu served as Zura Bio's CEO from the deal's close through April 2024 before transitioning to a director role, and Badial served as CFO of Zura Bio post-combination, meaning the team has direct experience operating a public biotech through a challenging post-SPAC period. JATT II raised $60 million in its April 2026 IPO, pricing 6 million shares at $10.00 as a stock-only SPAC with no warrants or rights attached, a structure that aligns sponsor and shareholder interests more tightly than traditional unit offerings. The vehicle traded at a premium post-IPO, reaching approximately $13.00 and delivering a +30% return from IPO with a +5% first-day pop. In June 2026, JATT II announced a definitive business combination with Talawar Therapeutics, a company developing bispecific antibodies for immunology and inflammatory diseases. The deal includes a $225 million oversubscribed PIPE at $10.00 per share alongside the $60 million in trust, for $285 million in expected gross proceeds assuming no redemptions. The PIPE syndicate includes blue-chip biotech investors Access Biotechnology, Bain Capital Life Sciences, and RA Capital. Talawar's lead asset, TALA-125 (an anti-IL-13 x anti-IL-18 bispecific for atopic dermatitis), is not expected to enter the clinic until 1Q 2027, with interim Phase 1 data in 4Q 2027 and Phase 2b proof-of-concept data only anticipated in 2H 2028. The stock surged approximately 13% on the deal announcement. The JATT track record presents a mixed picture. On one hand, the team has demonstrated an ability to source…
Full sponsor record →Why the sponsor matters
The thirty-second version, for anyone who has never traded a SPAC.
A SPAC is an empty listed company; the sponsor is the only substance it has before a deal. They pick the target, negotiate the terms, and typically hold founder shares — equity they received nearly free — which pay off for them even in deals that lose public holders money. A sponsor’s prior vehicles are the closest thing to evidence about how this one ends.
How the founder-share incentive works is covered in our plain-English guide to the sponsor promote.
In plain English
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Dilutionhow much of the company new shares take from you
Sponsor promote, PIPE shares, warrants and rights all issue stock that did not pay $10 for it. The headline deal value is before that; the effective value is after.
De-SPACthe day the SPAC becomes the real company
The shares stop being a claim on a pot of cash and start being equity in an operating business. Roughly 80% of recent de-SPACs traded below $10 within a year.